Table 1.
Characteristics of vaccine cost-effectiveness analyses (n = 243, all studies)
| Total | Herd immunity effects included, n (%) | No herd immunity effects, n (%) | |
|---|---|---|---|
| N (%) | 243 (100) | 44 (18) | 199 (82) |
| Publication year | |||
| 2000–2010 | 65 (27) | 5 (11) | 60 (30) |
| 2011–2014 | 70 (29) | 14 (32) | 56 (28) |
| 2015–2018 | 108 (44) | 25 (57) | 83 (42) |
| Funding source | |||
| Government or foundation | 118 (48) | 24 (55) | 94 (47) |
| Industry | 38 (16) | 9 (20) | 29 (15) |
| None/not determined | 64 (26) | 8 (18) | 56 (28) |
| Other | 23 (10) | 3 (7) | 20 (10) |
| Disease | |||
| Rotavirus | 53 (22) | 6 (14) | 47 (24) |
| HPV | 42 (17) | 4 (9) | 38 (19) |
| Pneumococcal disease | 41 (17) | 19 (43) | 22 (11) |
| Hepatitis | 21 (8) | 0 (0) | 21 (11) |
| Influenza | 19 (8) | 3 (7) | 16 (8) |
| Othera | 67 (28) | 12 (27) | 55 (6) |
| Quality score (range 1–7) | |||
| ≤ 4 | 62 (23) | 5 (11) | 57 (29) |
| > 4 | 181 (77) | 39 (89) | 142 (71) |
aOther category includes disease areas that have six or fewer studies in total, including Encephalitis (6), Rabies (6), Multiple disease areas (6), Dengue (5), Malaria (5), Measles (5), Cholera (4), Herpes zoster virus (4), Typhoid (4), Meningitis (3), Polio (3), Tetanus (3), Enterovirus 71 (2), Zika virus (2), brucellosis (1), Chagas disease (1), Echinococcosis (1), Hookworm (1), Norovirus (1), Q fever (1), Respiratory syncytial virus (1), Tuberculosis (1), Valley fever (1)